Your browser is no longer supported. Please, upgrade your browser.
Alterity Therapeutics Limited
Index- P/E- EPS (ttm)-0.41 Insider Own18.70% Shs Outstand34.51M Perf Week-7.05%
Market Cap43.13M Forward P/E- EPS next Y-0.01 Insider Trans0.00% Shs Float20.81M Perf Month-24.18%
Income-10.90M PEG- EPS next Q- Inst Own1.60% Short Float2.94% Perf Quarter-33.10%
Sales4.34M P/S9.94 EPS this Y40.00% Inst Trans-31.70% Short Ratio1.29 Perf Half Y-36.37%
Book/sh0.63 P/B1.44 EPS next Y- ROA-64.20% Target Price4.00 Perf Year-38.93%
Cash/sh- P/C- EPS next 5Y- ROE-73.60% 52W Range0.81 - 2.75 Perf YTD-32.10%
Dividend- P/FCF- EPS past 5Y9.00% ROI- 52W High-66.91% Beta1.58
Dividend %- Quick Ratio10.90 Sales past 5Y- Gross Margin- 52W Low12.28% ATR0.06
Employees11 Current Ratio10.90 Sales Q/Q- Oper. Margin- RSI (14)34.33 Volatility7.22% 6.14%
OptionableNo Debt/Eq0.00 EPS Q/Q67.80% Profit Margin- Rel Volume0.31 Prev Close0.89
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume473.15K Price0.91
Recom- SMA20-12.37% SMA50-22.80% SMA200-32.64% Volume147,042 Change2.24%
Nov-22-21 07:50AM  
Nov-09-21 07:30AM  
Nov-05-21 02:57AM  
Nov-04-21 07:30AM  
Oct-29-21 02:50AM  
Oct-19-21 05:08PM  
Sep-20-21 10:51AM  
Aug-04-21 08:39AM  
Jul-30-21 09:05AM  
Jul-15-21 09:52AM  
Jul-01-21 11:51AM  
Jun-23-21 09:21AM  
Jun-07-21 11:04AM  
Apr-29-21 08:30AM  
Apr-21-21 09:25AM  
Feb-26-21 07:45AM  
Feb-09-21 08:53AM  
Jan-07-21 08:00AM  
Dec-21-20 08:30AM  
Dec-09-20 09:46AM  
Nov-16-20 10:42AM  
Oct-26-20 10:03PM  
Aug-05-20 03:10PM  
Aug-04-20 09:07AM  
Aug-03-20 09:33PM  
Jul-30-20 06:49PM  
Jul-01-20 08:12AM  
Jun-29-20 11:14PM  
May-20-20 08:58PM  
Apr-30-20 04:35AM  
Apr-21-20 05:50PM  
Feb-21-20 07:15PM  
Nov-11-19 10:30PM  
Sep-12-19 11:07PM  
Jul-29-19 08:00AM  
Jul-11-19 09:31PM  
May-06-19 08:00AM  
May-03-19 08:00AM  
Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candidate is ATH434 that has completed Phase I clinical trial for the treatment of Parkinson's disease. It is also developing PBT2 that has completed Phase IIa clinical trial to treat Alzheimer's disease. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. Alterity Therapeutics Limited was incorporated in 1997 and is headquartered in Melbourne, Australia.